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Palavras-Chave Fadiga muscular; Co-ativação; EMG; Martin Vigorimeter; Jamar 
Dinamómetro 
Resumo Enquadramento: O critério exaustão para o diagnóstico de 
fragilidade é medido usualmente por questionários, que são 
subjetivos e dependem da perceção individual. O teste de 
resistência à fadiga (FR) foi desenvolvido como uma avaliação da 
exaustão para pessoas prostradas. No entanto, o Dinamómetro 
Jamar (JD) está a ser frequentemente utilizado para medir a força 
de preensão. Deste modo comparar os aparelhos é fundamental 
para compreender se a FR é análoga quando medida com os 
diferentes aparelhos. 
Métodos: Cinquenta e quatro participantes (29 do sexo feminino 
e 25 do sexo masculino; com uma média de idade de 39.98 ± 
18.09) que vivem independentemente na comunidade foram 
testados relativamente a funções musculares. 
O teste de FR, que mede o tempo durante o qual a força declina 
para 50% do seu máximo, foi também registado por 
eletromiografia (EMG). O que permitiu o cálculo da co ativação do 
músculo antagonista e ativação do agonista, e posteriormente a 
comparação entre a performance do teste com cada um dos 
aparelhos (com controlo das variáveis de género e idade). 
Resultados: A duração do teste FR é melhor quando se usa o 
VM do que quando se usa o JD. Em todos os momentos do teste 
FR a co ativação antagonista foi significativamente maior para VM 
em comparação com a do JD. Em contraste, o nível de ativação 
agonista foi significativamente maior com o JD em comparação à 
do VM. Durante o teste FR usando o VM, tanto a ativação do 
músculo agonista como a co ativação do antagonista diminuem 
significativamente (p <0,05). Enquanto utilizando o JD apenas foi 
observada diminuição significativa na co ativação. O delta da co 
ativação antagonista entre VM e JD foi significativamente 
relacionado com o delta do FR entre ambos os aparelhos. 
Conclusão: Os resultados sugerem que quando se utiliza o VM 
no teste FR induz uma exaustão muscular mais proeminente do 
que a utilização do JD, o que faz com que o VM seja mais 
adequado para medir a resistência à fadiga muscular. No entanto, 
estes resultados devem ser confirmados num estudo com uma 
população mais ampla. 
  
  
 
Key-words Muscle fatigue; Co activation; EMG; Martin Vigorimeter; Jamar 
Dynamometer 
Abstract Background: For the diagnosis of frailty exhaustion is a 
criteria currently measured by self-reported questionnaires, 
which are subjective and dependent on individual perception. 
The FR test has been developed as a bed side objective 
evaluation of muscle fatigue. The test was validated for the 
VM. However, the JD is frequently used to measure the grip 
strength. So the comparison of these devices is required to 
understand if FR is similar when measured with both devices. 
Methods: Fifty-four (29 female and 25 male; mean age: 39.98 
± 18.09) community-dwelling people were tested for muscle 
function. 
The Fatigue resistance (FR), which is the time during that grip 
strength drops to 50% of its maximum, was recorded with each 
device and simultaneous sEMG of the forearm muscles was 
obtained. The (co-)activation of agonist and antagonist 
muscles was calculated and compared with the differences 
between the performances with each device (controlling for 
gender and age). 
Results: FR was significantly better when measured with VM 
compared to JD. At all phases of the FR-test the antagonist 
muscle co-activation was significantly higher for VM compared 
to JD. In contrast, the agonist muscle activation level was 
significantly higher in JD compared to VM. When performing 
the FR-test with VM, both the agonist muscle activation and 
antagonist muscle co-activation decreased significantly 
(p<0.05). Whereas when using the JD, only a significant 
decrease in the antagonist muscle co-activation was observed. 
The difference in antagonist muscle activation between VM 
and JD was significantly related to the difference in FR 
between both devices. 
Conclusion: The results suggest that the FR-test when using 
the VM induces a more prominent muscle exhaustion than 
when using the JD, which makes the VM more suitable for 
measuring muscle fatigue resistance. However, these findings 
must be confirmed in a larger study population.  
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1. Introduction 
The world population of 60 years and older has doubled since 1980 and is forecast to 
reach 2 billion by 2050 (1). A positive aspect is that the number of older people who live 
dependently increases and is estimated to quadruple by 2050 in developing countries (1). This 
quick and dramatic demographic change has substantial implications for planning and providing 
health and social care. A major thread for independency at higher age is frailty. Frailty is a 
complex geriatric syndrome characterised by a state of increased vulnerability at higher age (2, 
3). This condition is characterized by several clinical manifestations such as sarcopenia, 
dynapenia, fatigue, sedentary lifestyle, malnutrition, cognitive decline and disability in activities 
of daily life (4, 5). Frailty is a typically unstable condition, which can be exacerbated by a 
multiplicity of triggers such clinical (disease, trauma, etc) and psychosocial (life events) origin 
(4). The most widely accepted approach of physical frailty is the phenotype which describes 
frailty in 5 components: exhaustion, low grip strength, unintentional weight loss, low physical 
activity and slow walking (6). Mainly the first two components, exhaustion and low grip strength, 
will be the focus of this work. 
Disability and frailty in older patients are closely related to sarcopenia (2, 7, 8) which is 
loss of muscle mass and strength that occurs with aging (9). Sarcopenia and frailty are strongly 
interrelated (2), and often assessed by maximal grip strength. Exhaustion in frailty is currently 
only assessed by self-reported questionnaires (5, 10), the inclusion of a physical test could 
contribute to a more objective evaluation. Bautmans et al. in a series of nine original studies (9, 
11-19) has introduced, refined and validated a new assessment method for muscle fatigue 
resistance (FR) as a direct and objective outcome parameter of the exhaustion component of 
frailty in elderly persons. The test measures the time during which grip strength drops to 50% of 
its maximum during sustained contraction (12). This test is now internationally accepted and 
several researchers as well as clinicians are using it. The FR test has been validated for the 
Martin Vigorimeter (VM)(12). Since this device is gentler for weak or painful joints (20) and 
allows performing a dynamic contraction (the rubber bulb is compressible), it is highly suitable to 
assess sustained maximal contractions in elderly subjects. However, many researchers and 
clinicians are using the Jamar Dynamometer (JD), a device designed to measure static grip 
strength. Grip strength measures obtained by the VM have been shown to be well correlated 
with those obtained with the JD (21). Although, until nowadays, no data regarding the FR test 
measured with the JD are available, hence limiting the implementation of the FR test. Validation 
of the FR test with the JD would improve the implementation in daily practice. Besides, the 
measurement of exhaustion in the frailty syndrome can be improved by the inclusion of the 
physical FR test. It is also important to investigate if there are significant differences in the 
muscular endurance between the different devices.  
In this work we studied the strength decay and simultaneous EMG during the FR test 
assessed by the VM and the JD. Thanks to the simultaneous EMG registration it was possible 
to investigate the co-activation of the extensor and flexor muscles.  
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In the first part of this thesis the major concepts such as frailty, sarcopenia and 
muscular fatigue are defined. Subsequently the research question and the main objectives of 
the study are elaborated, followed by the experimental part including methods and results 
sections. The final part is the discussion and the overall conclusions of the work. 
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2. Major concepts 
2.1 Frailty 
Aging-related dependency and disability is a huge concern (22). The literature reveals 
that frailty is a condition extremely related to dependency at higher age (1). Frailty is considered 
a geriatric syndrome of decreased reserve in multiple physiologic systems and reduced 
resistance to stressors, causing increased vulnerability for adverse health outcomes including 
falls, hospitalisation, institutionalization and mortality (2, 3, 23).  
It is now known that aging is not synonymous of frailty (4), as stressed by Wou and 
Conroy “Not all of the oldest old are frail, and not all frail people are aged” (10). Considering that 
frailty can appear in one-quarter of the elderly people, without pre-existing multiple co 
morbidities or disabilities, it is relevant understand how frailty develops (7).  
In spite of a distinct physiopathology, the underlying pathways leading to frailty are 
assumed to be part of a multidimensional entity comprising physical, psychological and 
sociological components, with a particular involvement of inflammatory processes, and changes 
in hormonal homeostasis and body composition (2). Frailty is not a synonym of aging neither of 
dependency, disability or co morbidities (10, 24).  
Fried et al. defined physical frailty according to five criteria: weight loss, exhaustion, low 
physical activity, slow walking speed and weak grip strength (6). Subjects showing 3 or more 
criteria are considered as frail; presence of one or two criteria is defined as pre-frailty; negative 
on all criteria is defined as healthy (6). There are many other scales to assess frailty (25), for 
example the list of variables used by the Canadian Study of Health and Aging to construct the 
70-item Frailty Index that analyses items together such as co morbidity, cognitive impairment 
and disability (26). Although most of it is hard to compare the measured outcome of these 
instruments with each other because of the differences in frailty instruments (25). Most of the 
instruments focus just on physical frailty (nutrition status and mobility), and only a few included 
items on three domains such physical, psychological and social domain (25, 27). Comparing 
these two approaches to frailty, both of them have demonstrated that adverse outcomes 
occurred more commonly among people who were frail (26). The physical component of frailty 
is the most studied until now (28). Despite the different criteria for diagnosis, the loss of muscle 
mass with aging is considered as a major cause of functional decline and disability (29), this 
means sarcopenia is the major component of frailty. Although they are not the same, there are 
an overlap range from 50% to 70% between this conditions (30). 
2.2 Sarcopenia 
Sarcopenia is an important change in body composition and function, it is described as 
a progressive and widespread decline in muscle mass, strength and physical performance in 
elderly people, which increase the risk for nursing home admissions and loss of independence, 
as well as an increase in weakness, falls and fractures (31). Low muscle mass is most often 
defined as a skeletal muscle mass index (muscle mass expressed by height² or as percentage 
of total body mass) between 1 and 2 (32, 33). Standard deviations (SD) below a young 
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reference group for class I sarcopenia (moderate) and lower than two SD for class II sarcopenia 
(severe) (32). It has been shown that sarcopenia is associated with functional impairment and 
disability and confirming that is a significant public health problem (34). The relevance of 
sarcopenia in the clinical decision making is underlined by the recommendation to include it in 
the comprehensive geriatric assessment (35). In 2010, the European Working Group on 
Sarcopenia in Older People (EWGSOP) proposed an operational definition for sarcopenia as 
well as a guide to standardize the evaluation of sarcopenia (36). Conceptually, sarcopenia is a 
term utilized to define the progressive and generalised loss of skeletal muscle mass and 
strength that increase the risk of adverse outcomes such as physical disability, poor quality of 
life and death (9, 31, 36). However, for clinical purposes, the EWGSOP proposed to include 
also the measurement of muscle strength (e.g. grip strength) and physical performance (e.g. 
walking speed) besides muscle mass assessment (8, 36). Despite the EWGSOP criteria, there 
is no conclusive definition of sarcopenia so far (37, 38).  
The main adverse health consequences of sarcopenia are falls and loss of 
independency, increased health costs, reduced quality of life and increased mortality (28, 30, 
31, 36, 37, 39, 40). Glucose regulation, hormone production, cellular communication and protein 
storage and turnover are also related impairments in physiological functions (8, 28, 41). With 
age, atrophy affects mostly type II fibres compared to type I (25–60% versus 0–25% reduced 
single fibre cross-sectional area (42). In general, the postural muscles show more type I fibres 
and the upper limbs more type II fibres (43).The muscle fibre atrophy is caused by a reduced 
rate of myofibrillar muscle protein synthesis and a higher catabolic activity at old age (42). 
Sarcopenia is present in about 5 to 10 % of persons over 65 years of age although the 
prevalence varied strongly according to the criteria used and with the region (30). Sarcopenia 
represented an estimated cost of about $18.5 billion in the United States in 2000, representing 
1.5% of total healthcare expenditures (34).  
More research is necessary to understand the nature of this syndrome in order to 
improve medical therapy and avoid the adverse consequences of it, manly the interaction of 
anabolic hormones and exercise (9).  
2.3 Muscle Fatigue 
In this paragraph, muscle fatigue is briefly explained after a short introduction of the 
neurophysiology of the muscular system. The muscular system is constituted by different kinds 
of muscular tissue (skeletal, smooth and cardiac muscles). The capacity of movement and 
consequently the independency in activities of daily living are possible thanks to the muscles 
that contract (43). The skeletal muscle is responsible for physical movements, as is the only one 
that is able to contract voluntarily. The contraction is always triggered by a neuronal stimulus, 
releasing acetylcholine in the neuromuscular junction and activating the sarcolema (43).  
These events can be measured via recoding the electrical activity of the muscle by 
electromyography (EMG, expressed in millivolts) (44). This measurement is possible as the 
cellular membranes (de)polarize inducing changes of electrical charges. The difference of 
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potential between the membrane of nervous cells and the muscular fibres is between -70 and -
90 mV (43).  
Fatigue is characterized as a decrease of the capacity to perform muscle work that usually 
follows a period of activity (45). Fatigue is a common feeling in humans, although it is 
experienced in different ways (43). Fatigue can occur in three potential places: the nervous 
system, the muscles or in the neuromuscular junction (43). The psychological fatigue is the 
most common type and finds its origin in the central nervous system (46). This fatigue and its 
duration depend on the mood state of the person (11, 46). Muscular fatigue can result from 
depletion of ATP which occurs in the muscle fibre (43, 45, 47). Synaptic fatigue occurs rarely, 
because is when the acetylcholine release might be insufficient to stimulate the muscles fibres 
(43). 
A new assessment to evaluate muscle FR as a direct and objective outcome parameter of 
the exhaustion component of frailty in elderly persons has been proposed by Bautmans et al. 
(12). In order to assess the muscular endurance in hospitalized elderly people a FR test was 
developed for elderly people based on grip strength (12). The test measures the time during 
which grip strength drops to 50% of its maximum value during sustained maximal contraction 
(12). Emphasizing the VM device is highly suitable to assess sustained maximal contractions in 
elderly subjects (48), since it is gentler on weak or painful joints (20) and allows performing a 
dynamic contraction (the rubber bulb is compressible). Nevertheless the JD was designed to 
measure static grip strength and is being used frequently, although it is heavier that the VM (48-
53). However they trigger different contractions, and had different until nowadays, no data 
regarding the FR test measured with the JD was available, thereby the implementation of the 
FR test is limited. The VM measures a isotonic contraction (the rubber bulb is compressible) 
and the JD measures a isometric contraction (the handle is not compressible) (48). Even though 
the grip strength had a high correlation between the two measurements (21), muscle fatigue 
might occur differently during sustained maximal grip effort (45).  
In addition, a supplementary muscle endurance outcome, denominated as Grip Work, was 
developed thought the integration of maximal grip strength and FR in order to improve the 
interpretation of FR scores (16). This parameter represents the physiologic work delivered by 
the handgrip muscles during the FR test. Grip work is graphically represented by the area under 
the curve with grip strength in the vertical and time in the horizontal axis (11, 16). Besides age 
and gender, several other parameters can influence FR and grip work as measured with the 
VM, among which physical activity, self-perceived fatigue, body composition, functional capacity 
and inflammatory processes (11-19). 
 There are neurophysiologic change that were related to induce dynapenia (age-related 
muscle weakness (54)), such as the deficit in maximal voluntary muscle activation (MVMA) and 
increased antagonist muscle co-contraction (55). The MVMA as pointed by Arnold & Bautmans, 
“The maximal voluntary muscle activation is reached when MU recruitment is complete and all 
recruited units are discharging at their maximal frequency” (56). The magnitude of co activation 
during muscular voluntary contractions (MVCs) is typically assessed by expressing EMG activity 
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in the antagonist muscle as a percentage of its activity when acting as an agonist during a 
maximal contraction (56). Co-activation appears to be higher in elderly compared to younger 
adults during isometric contractions (55, 56).  
3. Aim of the study 
This thesis is part of a larger research project comparing the strength decay during the 
FR test obtained by the VM and the JD in adult subjects of different ages and clinical condition. 
This thesis is based on the first series of community-dwelling adults included in the project, with 
a specific focus on agonist and antagonist muscle (co-)activation during the FR test.  
4. Methodology 
4.1 Study design 
This is a cross sectional (57), explorative study with a test-retest design (58). This study 
was the first results of a major project that is being developed.  
4.2 Participants 
Healthy community-dwelling adults were recruited via flyers and announcements in local 
media (journals, websites and local television) and/or through the students’ network. For the 
young (aged 18-30 years) healthy reference group, preferentially students of Vrije Universiteit 
Brussel (VUB, Brussels, Belgium) and Stichting Opleiding Musculoskeletale Therapie (SOMT, 
Amersfoort, The Netherlands) were approached for participation.  
In order to be eligible to participate in this study, the subjects had to meet all of the 
following inclusion criteria, respectively with the group that were include: 
 
a) Young, healthy subjects aged 18-30 years (reference group): completely healthy, no 
medication use, no impairments interfering with muscle FR test, normal physical activity (i.e. 
at least 150 minutes/week at moderate intensity but no competitive sports measured with 
The Yale Physical Activity Survey (59)). 
b) Community-dwelling subjects aged >30 years: living independently in the community, no 
functional disability of the dominant upper extremity (paresis/paralysis, tremor or recent 
surgery), normal cognitive functioning (Mini-Mental State Examination [MMSE] score 
>23/30(60)), living independently in the community. 
The exclusion criteria were pregnant women and in group community-dwelling subjects 
people who had an acute or uncontrolled condition, chronic inflammatory pathology and/or 
central nervous disease (e.g. Parkinson’s disease, Multiple Sclerosis, Cerebro-Vascular 
Accident). 
The study protocol was approved by the ethical committees of the Universitair 
Ziekenhuis Brussel (University hospital of the Vrije Universiteit Brussel, Brussels, Belgium) and 
 7 
 
Atrium-Orbis-Zuyd (Heerlen, The Netherlands). All participants gave their written informed 
consent.  
4.3 Measurements 
The data was collected between February and April 2015. FR and strength decay were 
assessed both by the MV and JD in a random order. The randomization was the technique used 
to create the initial equivalent between groups (58). Before the groups had the same 
characteristics with respect to the dependent variables and socio-demographic variables. This 
allows the groups to mach in such a way that the individual characteristics of participants are 
present in both groups. The technique used to decide on the participants group was 
heads or tails.  
4.3.1 Surface electromyography 
Some factors were report to interfere with the EMG data: influence of the subcutaneous 
tissue thickness,  effect of varying inter-electrode distances, orientation relative to muscle fiber 
direction,  position of electrodes relative to the innervations zone on amplitude values (61). In 
order to reduce these influences some procedures were taken carefully. First, the skin of the 
dominant forearm was prepared (44, 62, 63). The area of the muscle mid-belly was shaved and 
cleaned with 70% of ethyl alcohol (64). Two circular electrodes (4 cm diameter) were placed 
with an inter-electrode distance of 3,4 cm (61) on the muscle belly, located by palpation of the 
contraction of the muscle. The performance of contraction of each muscle was required by the 
following exercises:  
 The extensor digitorum brevis muscle the subject was asked to move the 
middle finger up and down,  
 The flexor digitorum superficialis muscle the subject was asked to squeeze the 
hand. 
 The reference electrode was placed on the proximal part of the Ulna.  
All raw sEMG signals were simultaneously sampled at 5000Hz (Butterworth 4
th
 order, 
band-pass 10-500Hz and notch filtered) and stored on a personal computer. 
4.3.2 Fatigue Resistance 
Tests were performed on the same day with at least one hour interval. FR scores of the 
first test were masked for assessor and participant during the second test. The FR test was 
performed by a modified digital manometer and Dynamometer G200 system, connected to a 
MPAQ universal amplifier (Maastricht Instruments) in order to appraise muscle fatigue curves. 
The modified VM and Dynamometer G200 had an identical rubber bulb and handle as 
respectively the original MV and JD (Figure 1 and 2), but were equipped with respectively a 
pressure and strength gauche that allow continuous registration of the strength decay during the 
FR test. The instrument setting of the Modified VM was characterized for large rubber bulb 
connected to a digital manometer and the values were recorded in kilopascal (KPa). In the other 
hand the values of G200 Dynamometer were recorded in Kilogram (Kg). 
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 Data acquisition was at 5000Hz and notch-filtered. Only the dominant hand was tested.  
 
Figure 1: Modified VM  
 
Figure 2: G200 Dynamometer 
During the FR test the participants needs to take a standard position (12, 20, 21). 
Seated on a chair, the shoulder adducted and neutrally rotated, elbow flexed at 90°, forearm in 
neutral position and wrist in light extension (0 to 30°) (20, 65). No support of elbow allowed (e.g. 
no use of arm rests allowed). During the performance using the modified VM the subject grasps 
the large rubber bulb with the thumb round one side of the rubber bulb and the four fingers 
around the other side of the rubber bulb (Figure 1). The connecting tube to the rubber bulb is 
oriented upwards. While during the performance using the G200 dynamometer the subject 
grasps the handle of the dynamometer with the thumb round one side of the handle and the four 
fingers around the other side (Figure 2). The grip strength display is oriented upwards. 
In order to obtain sEMG data of maximal finger extension (necessary in order to 
calculate the muscle activation level of the finger extensors during the FR-test) an isometric 
maximal finger extension test was performed. The subject was seated on a chair with the elbow, 
forearm and palmar part of the hand on a table; the fingers (2
nd
 – 5
th
) were outside unsupported 
outside the table. The subject was asked to extend the fingers as high and as hard as possible; 
the investigator manually pushed the fingers towards flexion sufficiently hard to overcome the 
extension strength of the participant. This test was repeated three 3 attempts were performed. 
The subject was asked to squeeze the large bulb of the modified VM / the handle of the 
G200 dynamometer as hard as possible. The highest of three attempts was noted as the 
maximal grip strength (in KPa / Kg). 
The same position as for the grip strength test of the participant’s hand and arm was 
adopted to perform the FR test. Participants were instructed to maintain the elbow in 90° flexion 
and were not allowed to see the readings on the manometer / dynamometer at any time during 
the procedure. The subject was instructed to squeeze again the large bulb of the modified VM/ 
the handle of the G200 dynamometer as hard as possible and to maintain this maximal effort as 
long as possible. The observer verifies that the starting strength corresponded to the maximal 
grip strength tested before and, if too low, encouraged the participant to squeeze as hard as 
possible. Standardized verbal encouragement (“Keep squeezing, don’t let go”) was given to the 
subject each time the pressure diminished. The test stopped when the grip strength dropped 
below 50% of its maximum and the subject could not increase the strength despite verbal 
encouragement. The time (in seconds) during which grip strength dropped to 75% and 50% of 
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its maximum was recorded as FR75% and FR50% respectively. The strength output (and 
sEMG) were synchronously and continuously recorded during the test and stored on a local 
computer until post-processing. 
Before every single test performed was essential calibrate the device correctly, this 
procedure was done (44, 66).  
4.5 Data Processing 
From the maximal isometric finger extension test sEMG data of the maximal finger 
extension was obtained. In figure 3, the 3 attempts can be differentiated. The red curve 
corresponds with the muscle activation of the muscle extensor, the yellow one corresponds with 
the muscle co activation of the flexors (Figure 3).  In the curve corresponding with extensor 
activation, the goal was to find the maximum level of muscle activity, which was described as 
maximal extension in mV. Once it was established in which attempt the maximal muscle activity 
was reached during the sEMG registration, this specific attempt was analyzed for a two second 
plateau (constant extensor activity). The root mean square (RMS) of the extensors and flexors 
muscle activation during the selected two seconds was gathered respectively from the red and 
yellow curve and named maximal extension RMS extension and maximal extension RMS 
flexion. 
 
Figure 3: Example of data obtained from the maximal finger extension 
During the maximal grip strength test the muscle activation of the flexors (yellow curve) 
and the extensors (red curve) of the forearm were simultaneous registered (Figure 4). After 
which the maximum level of muscle activation was searched in the curve of the flexor activation, 
this was described as maximal flexion in mV. Once identified which attempt contained the 
maximal level of muscle activity, a plateau of two seconds (constant flexor activity) was sought 
in that specific EMG registration.  The RMS of the extensors and flexors muscle activation and 
the strength during the selected two seconds was gathered respectively from the red, yellow 
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and purple curve and named maximal flexion RMS extension, maximal flexion RMS flexion  and 
maximal flexion RMS force.   
 
Figure 4: Example of data obtained from the maximum flexion 
From the curve representing strength in the FR test (purple curve) different values could 
be determined: maximal strength (F=100%), 75% of maximal strength (F=75%) and 50% of 
maximal strength (F=50%), as well as the timeframe in which these values were achieved 
(respectively T100%, T75% and T50%).  
Likewise, the RMS was calculated over a two second period for the extensors (FR RMS 
Tx extension) and flexor muscle activity (FR RMS Tx flexion) as well as the strength registration 
(FR RMS Tx force) during the FR test in the three moments (T100%, T75% and T50%). This two 
seconds period was calculated for maximal strength (T100%) by selecting exactly 1 second 
before and after of reaching max strength (Figure 5). The moment T75 was achieved, two 
consecutive seconds were searched where muscle strength was equal or less than the result of 
subtract two kPa/ 100 gram (respectively FR test measured via VM and JD) to the 75% of max. 
muscle strength. The two seconds period just before the subject reached 50% of max. strength 
was selected and the RMS was also calculated for muscle activity of the extensors, flexors and 
strength during that selected period. 
 
Figure 5: Example of data obtained from the FR test 
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Due to the data gathered from the maximal finger extension, maximal grip strength and 
FR test, we were able to determine the antagonistic co activation and agonistic activation for the 
three periods approached during the FR test.  
 
Subsequently the difference between both devices in muscle (co) activation  during the 
FR test was calculated for the time points T100%, T75% and T50%: 
4.6 Statistical analysis  
For all variables, descriptive statistics were calculated and distribution normality was 
verified using the Kolmogorov-Smimov Goodness of Fit test (58). Differences between genders 
and devices were analyzed using respectively Independent Samples t-test and the Paired 
Samples t-test. The Pearson’s correlation coefficient was calculated to determine the 
relationship between FR and agonistic and antagonistic muscle activation. Where relevant, 
partial correlation coefficients were computed, controlling for age and gender. Changes in 
muscle activation during the FR-test were analyzed using repeated-measures Analysis of 
Variance (ANOVA) with device (VM & JD) as between-subject factor and Bonferroni post-hoc 
testing. All statistics were performed using the IBM SPSS statistics version 22.0.0.2. 
Significance was set a priori at p<0.05. 
• Antagonistic co activation 
Antagonistic co activation T100 = FR RMS T100 extension / maximal extension * 100  
Antagonistic co activation T75 = FR RMS T75 extension / maximal extension * 100  
Antagonistic co activation T50 = FR RMS T50 extension / maximal extension * 100  
• Agonistic activation 
Agonistic activation T100 = FR RMS T100 Flexion / FR RMS T100 flexion 
Agonistic activation T50 = FR RMS T75 Flexion / FR RMS T100 flexion 
Agonistic activation T50 = FR RMS T50 Flexion / FR RMS T100 flexion 
• Delta antagonistic co activation 
Delta antagonistic co activation T100 = antagonistic co activation T100 (VM) - antagonistic co 
activation T100 (JD) 
Delta antagonistic co activation T75 = antagonistic co activation T75 (VM) - antagonistic co 
activation T75 (JD) 
Delta antagonistic co activation T50 = antagonistic co activation T50 (VM) - antagonistic co 
activation T50 (JD) 
 
•  Delta agonistic activation 
Delta agonistic activation T100 = activation flexion T100 (VM) - activation flexion T100 (JD) 
Delta agonistic activation T75 = activation flexion T75 (VM) - activation flexion T75 (JD) 
Delta agonistic activation T50 = activation flexion T50 (VM) - activation flexion T50 (JD) 
 
• Delta fatigue resistance 
Delta FR100 = FR100 (VM) - FR100 (JD) 
Delta FR75 = FR75 (VM) - FR75 (JD) 
Delta FR50 = FR50 (VM) - FR50 (JD) 
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5. Results 
The sample was constituted by 56 community-dwelling participants (30 female and 26 
male). However two of them were not compliant to the test instructions and thus excluded for 
the data analyses.  
As shown in table 1, female participants were significantly smaller than men. Female 
showed weaker hand grip strength with both devices than male. Compared to men, FR75 
measured with JD in women was shorter (p<0.05); for VM this difference was at the limit of 
significance (p=0.051). This difference between the genders disappeared for FR50. The other 
characteristics, like body weight or BMI did not reveal significant gender differences. 
Fatigue resistance (FR75 and FR50) was significantly better when measured with VM 
compared to JD. At all phases of the FR-test (T100%, T75% and T50%) the antagonist muscle 
co-activation was significantly higher for VM compared to JD (all p<0.05, see table 1 & Figure 
6). In contrast, the agonist muscle activation level was significantly higher in JD compared to 
VM at T75% and T50% (p<0.05, see table 1 & figure 6). When performing the FR-test with VM, 
both the agonist muscle activation and antagonist muscle co-activation decreased significantly 
(p<0.05), whereas when using the JD, only a significant decrease in the antagonist muscle co-
activation was observed (see figure 6). 
  
*Significant difference between time points (T100% and T75% and T100% and T50%) 
 
Figure 6: Percentage of muscle activation  and co activation during the FR test 
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Table 1: Participants characteristics stratified by gender (data expressed as mean ± SD
1
) 
Parameter Female Male Total 
Gender (n) N=29 N=25 N=54 
Age (y) 
              18-40 
              41-60  
              +60      
38.83 ± 17.16 
24.75 ± 1.18  (N=16) 
52.40 ± 1.34  (N=10) 
 68.67 ± 3.28  (N=3)       
41.32 ± 19.39 
28.19 ± 1.70   (N=16) 
   54.33 ± 3.84    (N=3) 
   69.83 ± 1.76    (N=6) 
39.98 ± 18.09 
26.47 ± 6.02  (N=32) 
52.85 ± 4.63  (N=13) 
 69.44 ± 4.48  (N=9) 
Height (kg)* 169.17 ± 6.29  181.29 ± 6.08 174.66 ± 8.65 
Weight (kg) 75.62 ± 20.09 84.59 ± 11.47 79.76 ± 17.13 
BMI (kg/m2) 26.88 ± 6.82 26.46 ± 4.57 26.69 ± 5.84 
F100_JD (Kg) * 31.11 ± 5.78  42.41 ± 8.24 36.35 ± 8.98 
F100_VM (KPa) * 71.14 ± 19.31  93.23 ± 20.06  81.36 ± 22.42 
FR75 † 
           JD (sec) * 
           VM (sec) * 
 
6.47 ± 3.74 
16.23 ± 9.51 
 
9.38 ± 4.99 
21.57 ± 10.11 
 
7.81 ± 4.56 
18.70 ± 10.07 
FR50 † 
           JD (sec) 
           VM (sec) 
 
33.91 ± 13.96  
62.61± 29.23  
 
30.74 ± 15.16 
60.77 ± 21.99 
32.44 ± 14.48 
61.76 ± 25.91 
Antagonist Muscle Co-activation T100%  † 
           JD 
           VM 
 
8.65 ± 2.71 
45.64 ± 12.55 
 
8.96 ± 2.72 
44.94 ± 13.67 
8.79 ± 2.70 
45.31 ± 12.96 
Antagonist Muscle Co-activation T75%  † 
           JD 
           VM 
 
7.90 ± 2.24 
36.38 ± 11.86 
 
8.37 ± 3.13 
35.18 ± 12.87 
8.12 ± 2.68 
35.82 ± 12.23 
Antagonist Muscle Co-activation T50%  † 
           JD 
           VM 
 
7.45 ± 2.55 
37.88 ± 24.14 
 
7.97 ± 2.88 
28.92 ± 10.40 
7.69 ± 2.69 
33.73 ± 19.42 
Agonist muscle Activity T75%  † 
           JD 
           VM 
 
95.39 ± 21.12 
84.21 ± 24.67 
 
98.59 ± 27.23 
75.77 ± 17.32 
96.87 ± 23.96 
80.30 ± 21.80 
Agonist muscle Activity T50% † 
           JD 
           VM 
 
94.75 ± 29.22 
66.44 ± 24.14 
 
90.90 ± 30.90 
59.82 ± 15.33 
92.97 ± 29.79 
63.37 ± 20.63 
Antagonist Muscle Co-activation T100% VM-JD  36.98 ± 11.08 35.98 ± 12.20 36.52 ± 11.51 
Antagonist Muscle Co-activation T75% VM-JD 28.48 ± 10.61 26.81 ± 10.78 27.71 ± 10.62 
Antagonist Muscle Co-activation T50% VM-JD* 30.43 ± 23.98 20.95 ± 9.39 26.04 ± 19.14 
Agonist muscle Activity T75% VM-JD -11.18 ± 29.51 -22.82 ± 27.68 -16.57 ± 29.01 
Agonist muscle Activity T50% VM-JD -28.31 ± 34.54 -31.08 ± 33.43 -29.59 ± 33.74 
Δ
2
 FR 75% 9.76 ± 8.95 12.20 ± 10.17 10.89 ± 9.52 
Δ FR 50% 28.70 ± 527.06  30.03 ± 26.78 29.32 ± 26.69 
*Significant difference between Male and Female (p<0.05) 
†Significant difference between VM and JD (p<0.05) 
  
                                                     
1
 SD- Standard deviation  
2
 Δ- Delta 
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As shown in table 2, a significant correlation (controlled for age and gender) was found 
between DeltaFR75 and delta antagonist muscle co activation T100% (r=.296, p<0.05) as well 
as between DeltaFR75 and delta antagonist muscle co activation at T75% (r=.276, p<0.05). 
Table 2: Correlation between the muscles activity and the time to fatigue during the FR test 
 Delta 
Antagonist 
Muscle Co-
activation 
T100% 
Delta 
Antagonist 
Muscle Co-
activation 
T75% 
Delta 
Antagonist 
Muscle Co-
activation 
T50%  
Delta Agonist 
muscle Activity 
T75%   
 
Delta Agonist 
muscle Activity 
T50%   
 
DeltaFR75 .296* .276* .200 -.029 .124 
DeltaFR50 .196 .177 -.057 -.051 .155 
Data represent Partial correlation coefficients controlled for age and gender *p<0.05. 
In table 3 the results are presented stratified by age and gender. The younger female 
and male showed significantly higher maximal grip strength for both devices compared to the 
older ones. The strongest group was the 18-40 year old, but this group had also the lowest FR 
values. This age effect in fatigability (FR50) was only significant in females. The group of 60+ 
showed significantly lower FR than group 18-40 when using the VM (18-40: 52.36 ± 19.26 vs. 
60+: 98.15 ± 58.75). But when using the JD device, FR was higher in the 40-60 age group (18-
40: 28.31 ± 12.30 vs. 40-60: 43.79 ± 13.40).  
In the male, the 18-40 group were taller and showed the strongest grip strength, 
whereas the group +61 was the weakest.  
No significant differences were found for muscle (co)-activation muscular. 
Table 3: Participants characteristics by gender and age (expressed as mean ± SD) 
Female 
 Age group  
18-40 years 41-60 years 60+ years 
 N=16 N=10 N=3 
Height (kg) $ 171.50 ± 6.28 † 168.30 ± 4.08 # 159.67 ± 0.58 
Weight (kg) 71.42 ± 17.64 85.78 ± 24.41 67.53 ± 5.22 
BMI (kg/m2) 24.83 ± 5.66 30.27 ± 8.37 26.53 ± 2.05 
F100 
      JD (Kg)    $    
      VM (KPa) $ 
 
32.31 ± 4.15 * 
77.18 ± 12.50 † 
 
31.55 ± 7.01 # 
68.02 ± 24.29 
 
23.30 ± 3.69 
46.09 ± 6.91 
FR75  
           JD (sec)  
           VM (sec)  
 
6.57 ± 3.37 
14.97 ± 7.52 
 
7.06 ± 4.63 
17.84 ± 10.91 
 
3.92 ± 1.77 
17.51 ± 16.72 
FR50  
           JD (sec) $ 
           VM (sec) $ 
 
28.31 ± 12.30 * 
52.36 ± 19.26 † 
 
43.79 ± 13.40 
68.36 ± 25.05 
 
30.84 ± 5.70 
98.15 ± 58.75 
Antagonist Muscle Co-activation T100%   
           JD 
           VM 
 
8.10 ± 2.81 
43.28 ± 13.30 
 
9.54 ± 2.63 
46.60 ± 10.97 
 
8.64 ± 2.51 
55.01 ± 12.46 
Antagonist Muscle Co-activation T75%   
           JD 
           VM 
 
7.79 ± 2.24 
35.25 ± 10.76 
 
8.15 ± 2.56 
36.51 ± 13.83 
 
7.65 ± 1.64 
41.96 ± 13.51 
Antagonist Muscle Co-activation T50%   
           JD 
           VM 
 
8.06 ± 2.87 
40.72 ± 30.38 
 
6.57 ± 1.88 
33.96 ± 15.25 
 
7.12 ± 2.55 
35.81 ± 6.19 
Agonist muscle Activity T75%   
           JD 
           VM 
 
101.25 ± 24.88 
88.20 ± 28.33 
 
90.59 ± 13.11 
80.64 ± 15.74 
 
80.19 ± 9.52 
74.89 ± 32.65 
Agonist muscle Activity T50%  
           JD 
           VM 
 
98.94 ± 26.32 
72.74 ± 25.22 
 
96.54 ± 34.26 
59.80 ± 23.59 
 
66.43 ± 10.90 
54.97 ± 12.09 
Δ FR 75% 8.40 ± 6.48 10.78 ± 9.77 13.60 ± 18.30 
Δ FR 50% $ 
24.05 ± 14.52 † 24.57 ± 21.37 # 
 
67.31 ± 64.19 
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Male 18-40 years 41-60 years 60+ years 
 N=16 N=3 N=5 
Height (kg)$ 182.88 ± 5.33 † 182.67 ± 6.81 175.40 ± 5.32 
Weight (kg) 83.54 ± 12.15 93.33 ± 7.57 82.68 ± 10.40 
BMI (kg/m2) 25.14 ± 3.91 27.97 ± 4.10 29.22 ± 5.62 
F100 
      JD (Kg)         
      VM (KPa) $ 
 
44.08 ± 8.00 
101.47 ± 16.90 † 
 
43.77 ± 8.54 
95.30 ± 8.79 
 
37.31 ± 7.95 
70.22 ± 13.77 
FR75  
           JD (sec)  
           VM (sec)  
 
9.25 ± 4.82 
23.45 ± 11.33 
 
6.37 ± 3.86 
17.95 ± 10.63 
 
11.23 ± 5.86 
18.39 ± 5.36 
FR50  
           JD (sec) 
           VM (sec) 
 
27.47 ± 12.01 
57.85 ± 15.68 
 
32.59 ± 26.83 
63.77 ± 28.68 
 
38.55 ± 16.54 
67.07 ± 34.27 
Antagonist Muscle Co-activation T100%   
           JD 
           VM 
 
8.57 ± 2.32 
41.43 ± 12.49 
 
8.47 ± 2.32 
43.24 ± 10.48 
 
10.24 ± 3.93 
55.14 ± 14.77 
Antagonist Muscle Co-activation T75%   
           JD 
           VM 
 
8.56 ± 3.19 
33.43 ± 11.09 
 
6.78 ± 1.30 
31.19 ± 6.07 
 
8.64 ± 3.77 
41.83 ± 18.39 
Antagonist Muscle Co-activation T50%   
           JD 
           VM 
 
8.08 ± 2.74 
27.49 ± 9.72 
 
7.63 ± 1.87 
26.61 ± 8.20 
 
7.86 ± 3.96 
33.90 ± 13.00 
Agonist muscle Activity T75%   
           JD 
           VM 
 
104.75 ± 30.41 
75.60 ± 12.88 
 
91.06 ± 20.76 
79.12 ± 8.12 
 
85.93 ± 16.24 
74.54 ± 30.12 
Agonist muscle Activity T50%  
           JD 
           VM 
 
95.71 ± 34.41 
60.89 ± 16.76 
 
88.06 ± 31.00 
61.89 ± 13.00 
 
79.48 ± 20.31 
55.93 ± 13.91 
Δ FR 75% 14.20 ± 10.50 11.58 ± 7.22 7.17 ± 10.04 
Δ FR 50% 30.39 ± 15.87 31.18 ± 47.39 28.52 ± 42.25 
$ Significant difference between age group 
* Significant difference between age group 18-40 and 41-60 
†Significant difference between age group 18-40 and 61+ 
#Significant difference between age group 40-60 and 61+ 
The Bonferroni post-hoc testing was used to compare the variables between age groups 
6. Discussion 
The first aim of this study was to validate the FR test when performing with JD, 
comparing the muscle fatigue outcomes obtained by the VM and the JD in dwelling community 
subjects of different ages. The second aim was to study the co-activation of the arm extensors 
and flexors during the FR test.  
Even though the reliability of both JD and the VM has been evaluated in different 
populations (49, 50, 52), to our knowledge, these two types of instruments have never been 
compared measuring the FR test. Most studies of muscle function of elderly adults have 
focused on strength (20, 48, 51), thereby overlooking muscle fatigue as a potentially important 
link to normal activities of daily living requiring sub maximal sustained activity rather than 
maximal efforts (67, 68).  
This study was in agreement with the previous results that the men are stronger than 
women (21, 48, 51). Since this thesis describes the first subjects included in a still ongoing 
research project, the sample size was not equally distributed among the age-subgroups, thus 
data must be interpreted with caution. As expected, elderly people showed less grip strength 
than younger ones (49, 53, 69).  
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Although a very high correlation between VM and JD has been described concerning 
grip strength (21), this was not confirmed for muscle FR. Emphasizing that muscle fatigue is a 
distinct parameter of muscle strength, as happen in knee extensors and flexor muscles (68). 
The sample was large enough to demonstrate a significant difference in FR between the 
two devices. FR50 was in average 29 seconds better when performed using VM than the JD. 
This difference can be related to the type of contraction, which influences the muscle 
fatigue(70).  
During the FR-test, strength dropped more rapidly to 75% of its maximum in female 
compared to male, but for FR50 the gender effect disappeared. The gender differences in 
muscle fatigability are still controversial and depend on specific muscle groups (71). 
In all age groups we found a significant difference for FR between the devices. 
However, on both devices FR increased with age. Although, there was an exception for JD, 
where the middle-age group showed better FR compared to the younger and older ones. This 
can be due to the unbalanced proportions in age subgroups, effects of motivation or the feeling 
of pain (72). In addition age has previously been shown to be a predictor of fatigability, as was 
demonstrated in human adductor pollicis muscle during contractions of short duration and 
intermittent exercise (73).  
The sEMG data revealed significant differences in muscle (co)activation during the FR 
test when comparing VM to JD (74). The antagonist co-activation was more pronounced when 
using the VM, whereas the agonist activation was greater when using the JD. This difference 
might be related to differences in the position of the wrist during the FR test (65), although this 
was very similar for both devices.  On the other hand, the greater antagonist co activation when 
using the VM can positively impact the FR since antagonist co-activation  is related to a better 
stabilization of the joint (55). Besides, previous studies showed that dynamic contractions (the 
rubber bulb of the VM is compressible and thus movement of the fingers is possible) were 
associated with greater FR compared to isometric ones (the handle of the JD is rigid) (70). Our 
data suggest that the FR-test when using the VM induces a more prominent muscle exhaustion 
than when using the JD. However, it remains unclear why grip strength declines so rapidly when 
using the JD, since agonist muscle activation decreased much less than when using the VM. 
Interestingly, the the difference in antagonist muscle co-activation at T50% (VM value - JD 
value) was higher in female. This could be related with the greater FR in women (71), but more 
investigation is required to confirm this relationship. 
6.1 Limitations and future perspectives 
In this study there are some limitations. First, the results regarding age-differences must 
be interpreted carefully since the study population was not equally distributed over the age-
groups. However, this are the first results of a bigger ongoing project, and these first analyses 
must be confirmed when a larger group will be included. 
In addition, the sample did not include disable people. Therefore, no conclusions can be 
drawn with regard to the comparability of the devices when used in people with impairments. 
This will be explored in the future project.  
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7. Conclusion 
Fatigue resistance was significantly better when measured with VM compared to JD. At 
all phases of the FR-test (T100%, T75% and T50%) the antagonist muscle co-activation was 
significantly higher for VM compared to JD. In contrast, the agonist muscle activation level was 
significantly higher in JD compared to VM at T75% and T50%. When performing the FR-test 
with VM, both the agonist muscle activation and antagonist muscle co-activation decreased 
significantly (p<0.05), whereas when using the JD, only a significant decrease in the antagonist 
muscle co-activation was observed. Our results suggest that the FR-test when using the VM 
induces a more prominent muscle exhaustion than when using the JD, which makes the VM 
more suitable for measuring muscle FR. However, these findings must be confirmed in a larger 
study population. 
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